| Simian Adenovirus and Hybrid Adenoviral Vectors MDJ Dicks, MG Cottingham, AVS Hill, S Gilbert US Patent App. 18/511,357, 2024 | | 2024 |
| Mesalamine for Maintenance Therapy in Ulcerative Colitis: How much, How Long? MP Sparrow, WC Lim, SB Hanauer Crohn's Disease, 115-118, 2024 | 1 | 2024 |
| Validation of a multiplexed immunoassay for use in vaccine clinical trials and immunology studies of pre-erythrocytic malaria L Stockdale, S Provstgaard-Morys, D Bellamy, D Woods, K Rapi, A Bajer, ... | | 2024 |
| The Genomic Landscape of Oceania CD Quinto-Cortés, CB Jonas, S Vieyra-Sánchez, S Oppenheimer, ... arXiv preprint arXiv:2405.09216, 2024 | | 2024 |
| High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response AJ Mentzer, AT Dilthey, M Pollard, D Gurdasani, E Karakoc, T Carstensen, ... Nature Medicine, 1-11, 2024 | 2 | 2024 |
| The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study N Schmit, HM Topazian, HM Natama, D Bellamy, O Traoré, MA Somé, ... The Lancet Infectious Diseases 24 (5), 465-475, 2024 | 6 | 2024 |
| Adenoviral vector SC Gilbert, AVS Hill, MG Cottingham, M Dicks, SJ Morris, A Douglas US Patent 11,970,709, 2024 | | 2024 |
| Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture X Lv, J Martin, H Hoover, B Joshi, M Wilkens, DA Ullisch, T Leibold, ... Iscience 27 (3), 2024 | 1 | 2024 |
| Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised … SN Faust, R Haynes, CE Jones, N Staplin, E Whittaker, T Jaki, E Juszczak, ... The Lancet Child & Adolescent Health 8 (3), 190-200, 2024 | 6 | 2024 |
| OPEN ACCESS EDITED BY PB Fourie, R Pandey, I Viana, SM Dennison, GD Tomaras, U Wille-Reece, ... Methods in Vaccines and Molecular Therapeutics: 2022, 93, 2024 | | 2024 |
| New Hope Against Malaria D Wirth, A Hill, F Osier 2024 AAAS Annual Meeting, 2024 | | 2024 |
| Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial MS Datoo, A Dicko, H Tinto, JB Ouédraogo, M Hamaluba, A Olotu, ... The Lancet 403 (10426), 533-544, 2024 | 48 | 2024 |
| Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture H Schurz, V Naranbhai, TA Yates, JJ Gilchrist, T Parks, PJ Dodd, M Möller, ... Elife 13, e84394, 2024 | 4 | 2024 |
| Simian adenovirus and hybrid adenoviral vectors MDJ Dicks, MG Cottingham, AVS Hill, S Gilbert US Patent 11,857,640, 2024 | | 2024 |
| Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA J Doritchamou, MA Nielsen, A Chêne, NK Viebig, LE Lambert, AF Sander, ... Lab Animal 52 (12), 315-323, 2023 | | 2023 |
| Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms S Reinke, E Pantazi, GR Chappell, A Sanchez-Martinez, R Guyon, ... Cell Reports Medicine 4 (11), 2023 | 3 | 2023 |
| Mexican Biobank advances population and medical genomics of diverse ancestries M Sohail, MJ Palma-Martínez, AY Chong, CD Quinto-Cortés, ... Nature 622 (7984), 775-783, 2023 | 22 | 2023 |
| Injectable core-shell microspheres deliver prime-boost immunisation in a single shot R Guyon, L Bau, S Reinke, A Salman, A Hill, E Stride, A Milicic | | 2023 |
| Injectable core-shell microspheres deliver prime-boost immunisation in a single shot A Milicic, R Guyon, L Bau, S Reinke, A Salman, A Hill, E Stride | | 2023 |
| Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial D Jenkin, D Wright, PM Folegatti, A Platt, I Poulton, A Lawrie, N Tran, ... The Lancet Infectious Diseases 23 (8), 956-964, 2023 | 8 | 2023 |
